---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-24-000027"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:27:33.423546+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Senti Bio reports FY2023 net loss of $71.1M; cash runway into Q1 2025; IND cleared for SENTI-202 AML therapy

## Summary
- Net loss for FY2023 was $71.1M ($1.60/share) vs $58.2M in FY2022.
- Cash, cash equivalents and short-term investments of $35.9M at 12/31/2023; plus $18.9M GeneFab receivable to fund into Q1 2025.
- R&D expenses $32.2M (FY2023), G&A $37.2M; net loss includes $12.3M gain from discontinued operations and $25.7M impairment.
- FDA cleared IND for SENTI-202 (logic-gated CAR-NK for AML); first patient dosing expected Q2 2024, initial efficacy data by year-end 2024.
- Collaboration with Celest for SENTI-301A (HCC) in China; first patient dosing expected Q2 2024.

## SEC filing metadata
- accession: 0001854270-24-000027
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000027/0001854270-24-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000027/snti-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-24-000027
- JSON: https://secwatch.observer/filing/0001854270-24-000027.json
- Plain text: https://secwatch.observer/filing/0001854270-24-000027.txt

## Key facts
- Earnings Releases
  Senti Biosciences, Inc. reported the year ended December 31, 2023 results: net income Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended December 31, 2023. Net loss for, EPS $0.42 per basic and diluted share (quarter) and $1.60 per share (year).
  - Period: the year ended December 31, 2023
  - Net income: Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended December 31, 2023. Net loss for
  - EPS: $0.42 per basic and diluted share (quarter) and $1.60 per share (year)
  - Result: reported results
  source text: On March 21, 2024, Senti Biosciences, Inc. issued a press release announcing its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000027/0001854270-24-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.